Investors have mostly had one reaction to drugmakers’ earnings this quarter: Slam that big red “sell” button, and slam it hard.
The latest no good, very bad earnings season started with Johnson & Johnson , which on Oct. 17 raised its full-year guidance and announced third quarter earnings that beat Wall Street estimates. Shares fell 0.9% anyhow, eventually sliding to a 52-week low on October 27. The selloffs came at a low ebb in investor sentiment around big pharma, with the exception of the two companies behind the new anti-obesity drugs, Eli Lilly and Novo Nordisk . While Lilly’s shares are up 55.8% this year, and Novo’s are up 45.5%, the rest of the sector is trailing the market. In a year when the S&P 500 is up 13.5%, Pfizer is down 39%, Bristol Myers down 26.7%, Merck down 6.6%, and Johnson & Johnson down14.3%.
Despite all those headwinds, shares of a few of the drugmakers still seem cheap, especially after the recent selloffs. One is Merck. “We see MRK’s diversified pipeline/portfolio…as being increasingly well-equipped with commercial opportunities with the potential to generate sustained growth over the intermediate and longer term,” Goldman Sachs analyst Chris Shibutani wrote in an October 27 note. Shibutani has a Buy rating and a $131 target price on the stock.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: Investingcom - 🏆 450. / 53 続きを読む »
ソース: Forbes - 🏆 394. / 53 続きを読む »
ソース: axios - 🏆 302. / 63 続きを読む »